for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Exelixis, Inc.

EXEL.OQ

Latest Trade

19.56USD

Change

-0.01(-0.05%)

Volume

1,855,352

Today's Range

19.46

 - 

20.04

52 Week Range

13.43

 - 

25.31

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
19.57
Open
19.64
Volume
1,855,352
3M AVG Volume
53.45
Today's High
20.04
Today's Low
19.46
52 Week High
25.31
52 Week Low
13.43
Shares Out (MIL)
302.91
Market Cap (MIL)
5,927.88
Forward P/E
21.60
Dividend (Yield %)
--

Next Event

Exelixis Inc at Cantor Fitzgerald Global Healthcare Conference

Latest Developments

More

Exelixis Posts Q2 Earnings Per Share Of $0.25

Exelixis And Aurigene Enter Into Exclusive Collaboration

Exelixis Updates Phase 1b Cosmic-021 Trial Of Cabozantinib In Combination With Atezolizumab In Patients With Advanced Solid Tumors

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Exelixis, Inc.

Exelixis, Inc. is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company's cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors. The Company's CABOMETYX tablets are approved for previously treated advanced kidney cancer and COMETRIQ capsules are approved for progressive, metastatic medullary thyroid cancer. The third product, Cotellic, is a formulation of cobimetinib, a selective inhibitor of MEK is approved as part of a combination regimen to treat advanced melanoma. Both cabozantinib and cobimetinib have shown potential in a range of forms of cancer and are the subjects of broad clinical development programs. The Company's XL888 is a small molecule oral inhibitor of Heat Shock Protein 90 (HSP90), a molecular chaperone protein.

Industry

Biotechnology & Drugs

Contact Info

1851 Harbor Bay Pkwy

+1.650.8377000

http://www.exelixis.com

Executive Leadership

Stelios B. Papadopoulos

Independent Chairman of the Board, Co-Founder

Michael M. Morrissey

President, Chief Executive Officer, Director

Christopher J. Senner

Chief Financial Officer, Executive Vice President

Gisela M. Schwab

President - Product Development and Medical Affairs, Chief Medical Officer

Peter Lamb

Executive Vice President - Scientific Strategy, Chief Scientific Officer

Key Stats

2.00 mean rating - 12 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.2K

2017

0.5K

2018

0.9K

2019(E)

0.9K
EPS (USD)

2016

-0.280

2017

0.490

2018

2.210

2019(E)

0.906
Price To Earnings (TTM)
9.53
Price To Sales (TTM)
6.52
Price To Book (MRQ)
3.98
Price To Cash Flow (TTM)
9.09
Total Debt To Equity (MRQ)
0.01
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
54.75
Return on Equity (TTM)
50.23

Latest News

BRIEF-Exelixis Says No New Safety Signals Were Identified With Combination Of Cobimetinib And Atezolizumab

* EXELIXIS - ON JUNE 19 INFORMED BY GENENTECH, IMSPIRE170, PHASE 3 TRIAL EVALUATING COMBINATION OF COBIMETINIB & ATEZOLIZUMAB DID NOT MEET PRIMARY ENDPOINT

BRIEF-Exelixis Appoints Andrew Peters To Newly Created Position Of Vice President, Strategy

* EXELIXIS APPOINTS ANDREW R. PETERS TO NEWLY CREATED POSITION OF VICE PRESIDENT, STRATEGY Source text for Eikon: Further company coverage:

BRIEF-Exelixis Says Phase 3 Imblaze370 Study Did Not Meet Its Primary Endpoint Of Improving Overall Survival Vs Regorafenib

* EXELIXIS PROVIDES UPDATE ON IMBLAZE370 PHASE 3 PIVOTAL TRIAL OF ATEZOLIZUMAB AND COBIMETINIB IN PATIENTS WITH HEAVILY PRETREATED LOCALLY ADVANCED OR METASTATIC COLORECTAL CANCER

BRIEF-Exelixis Inc Q1 Earnings Per Share $0.37

* EXELIXIS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-Exelixis And Invenra Enter Into Collaboration To Develop Novel Biologics To Treat Cancer

* EXELIXIS AND INVENRA ENTER INTO COLLABORATION TO DISCOVER AND DEVELOP NOVEL BIOLOGICS TO TREAT CANCER

BRIEF-Exelixis Says CEO Michael Morrissey's FY 2017 Total Compensation Was $9.4 Mln VS $6.3 Mln

* EXELIXIS INC SAYS CEO MICHAEL MORRISSEY'S FY 2017 TOTAL COMPENSATION WAS $9.4 MLN VS $6.3 MLN IN 2016 - SEC FILING Source text: (https://bit.ly/2Hi8UXj) Further company coverage:

BRIEF-Exelixis Says Board Increased Size Of Board To 12 Members

* EXELIXIS SAYS BOARD INCREASED SIZE OF BOARD TO 12 MEMBERS - SEC FILING Source text: (https://bit.ly/2uWDtwR) Further company coverage:

BRIEF-Exelixis Says Ipsen received validation of the application for variation to the Cabometyx

* EXELIXIS’ PARTNER IPSEN ANNOUNCES EMA VALIDATION OF THE APPLICATION FOR A NEW INDICATION FOR CABOMETYX® (CABOZANTINIB) FOR PREVIOUSLY TREATED ADVANCED HEPATOCELLULAR CARCINOMA

BRIEF-Exelixis' Partner Ipsen Announces Positive CHMP Opinion For Cabometyx

* EXELIXIS' PARTNER IPSEN ANNOUNCES POSITIVE CHMP OPINION FOR CABOMETYX FOR PREVIOUSLY UNTREATED INTERMEDIATE- OR POOR-RISK ADVANCED RENAL CELL CARCINOMA

BRIEF-Exelixis Submits U.S. Supplemental NDA For Cabometyx

* EXELIXIS SUBMITS U.S. SUPPLEMENTAL NEW DRUG APPLICATION FOR CABOMETYX (CABOZANTINIB) FOR PREVIOUSLY TREATED ADVANCED HEPATOCELLULAR CARCINOMA Source text for Eikon: Further company coverage:

BRIEF-Daiichi Sankyo's Regulatory Submission Triggers $20 Mln Milestone Payment To Exelixis​

* CO ANNOUNCES COLLABORATOR DAIICHI SANKYO'S SUBMISSION OF REGULATORY FILING FOR ESAXERENONE (CS-3150) IN JAPAN

BRIEF-Exelixis Posts Q4 Earnings Per Share $0.12

* EXELIXIS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-Exelixis Announces Results From A Phase 2 Trial Of Cabozantinib In The First-Line Treatment Of Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma

* EXELIXIS ANNOUNCES RESULTS FROM A PHASE 2 INVESTIGATOR-SPONSORED TRIAL OF CABOZANTINIB IN THE FIRST-LINE TREATMENT OF METASTATIC RADIOIODINE-REFRACTORY DIFFERENTIATED THYROID CARCINOMA

BRIEF-Exelixis Announces Updated Phase 1 Trial Results For Cabozantinib

* EXELIXIS ANNOUNCES UPDATED PHASE 1 TRIAL RESULTS FOR CABOZANTINIB IN COMBINATION WITH NIVOLUMAB WITH OR WITHOUT IPILIMUMAB IN REFRACTORY GENITOURINARY (GU) TUMORS Source text for Eikon: Further company coverage:

BRIEF-Ipsen And Exelixis Announce Phase 3 Trial Results Of Cabozantinib Showing Benefit In Hepatocellular Carcinoma Patients

* EXELIXIS AND IPSEN ANNOUNCE PHASE 3 TRIAL RESULTS OF CABOZANTINIB DEMONSTRATING SIGNIFICANT OVERALL SURVIVAL BENEFIT IN PATIENTS WITH PREVIOUSLY TREATED ADVANCED HEPATOCELLULAR CARCINOMA

BRIEF-Exelixis Enters Into Exclusive Collaboration And License Agreement With Stemsynergy Therapeutics

* EXELIXIS - ENTERED INTO EXCLUSIVE COLLABORATION AND LICENSE AGREEMENT WITH STEMSYNERGY THERAPEUTICS

BRIEF-Exelixis Announces Amendment To Protocol For Phase 1B Trial Of Cabozantinib In Combination With Atezolizumab

* EXELIXIS INC - AMENDMENT TO PROTOCOL FOR PHASE 1B TRIAL OF CABOZANTINIB IN COMBINATION WITH ATEZOLIZUMAB

Pfizer, Exelixis cancer drugs get FDA approval for wider use

Cancer treatments from Pfizer Inc and Exelixis Inc on Tuesday won approval from the U.S. Food and Drug Administration for expanded use in previously untreated patients.

BRIEF-Exelixis Announces FDA Approval Of Cabometyx Tablets For Previously Untreated Advanced Renal Cell Carcinoma

* EXELIXIS ANNOUNCES U.S. FDA APPROVAL OF CABOMETYX® (CABOZANTINIB) TABLETS FOR PREVIOUSLY UNTREATED ADVANCED RENAL CELL CARCINOMA

BRIEF-FDA Says Approved Exelixis' sNDA For Patients With Previously Untreated Advanced RCC

* FDA SAYS APPROVED EXELIXIS' SNDA FOR PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED RCC

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up